In line with the 8201, Hengrui Pharmaceutical plans the HER2 ADC in this way

Recently, Hengrui Pharmaceutical exchanged plans for SHR-A1811.

SHR-A1811 for injection is an antibody drug conjugate independently developed by Hengrui Pharmaceutical, targeting HER2, which can bind to and endocytose tumor cells expressed by HER2, release toxins through protease cleavage in tumor cell lysosomes, induce cell cycle arrest and induce apoptosis of tumor cells.

SHR-A1811 has carried out a number of phase I.~III. clinical studies, covering advanced solid tumors expressed or mutated by HER2, advanced gastric cancer or gastroesophageal junction adenocarcinoma, colorectal cancer, advanced non-small cell lung cancer, metastatic breast cancer, etc.

The 1811 is the second generation HER2-ADC. Characteristic shearable joints, excellent effectiveness and controllable safety.

1 The safety is better, and the incidence of interstitial pneumonia is less than 10%, which is a big point of difference. Other related hematotoxicity does not change much, and the onset of action requires a higher intensity of the chemical part, and hematotoxicity cannot be avoided.

2 At the same time, the clinical practice of HER2 low expression has been carried out, and it has also been expanded in lung cancer, cholangiocarcinoma, urothelial carcinoma, etc.

3 Overseas trials are not currently planned, and overseas companies can cooperate if they are interested. The Nectin-4 ADC is second in the world.

4 There is no problem with the patent, several ADCs use the same linker and toxin.

SHR-A1811, proposed by the Center for Drug Evaluation of the National Medical Products Administration, is included in the public list of breakthrough therapy varieties for patients with recurrent or metastatic breast cancer who are positive for human epidermal growth factor receptor 2 (HER2); For patients with recurrent or metastatic breast cancer with low expression of human epidermal growth factor receptor 2 (HER2), two designations were obtained on the same day for inclusion in breakthrough therapy.